Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome

Expert Opinion on Emerging Drugs

Volumn 12, Issue 3, 2007, Pages 461-477

  Bosma, Karen J ^a   Lewis, James F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Clinical trial; Drug therapy; Inflammatory mediator; Surfactant

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BERACTANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALFACTANT; COMPLEMENT INHIBITOR; DX 890; EPI HNE 4; FLUOROVENT; GAMMA LINOLENIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ICOSAPENTAENOIC ACID; INASURF; KETOCONAZOLE; LEUKOCYTE ELASTASE INHIBITOR; LIPOPROSTAGLANDIN E1; LISOFYLLINE; LUCINACTANT; LUSUPULTIDE; METHYLPREDNISOLONE; NITRIC OXIDE; PERFLUOROOCTYL BROMIDE; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN E1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RELTRAN; SALBUTAMOL; SALBUTAMOL SULFATE; SIVELESTAT; TP 10; TP 20; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; FLUOROCARBON; LUNG SURFACTANT; NEW DRUG; RESPIRATORY TRACT AGENT; VASODILATOR AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CAUSE OF DEATH; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; FLUID THERAPY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SURVIVAL RATE; ANIMAL; CHEMISTRY; DRUG DESIGN; INHALATIONAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT SELECTION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; FLUOROCARBONS; HUMANS; MULTIPLE ORGAN FAILURE; NEUTROPHILS; NITRIC OXIDE; PATIENT SELECTION; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34748918333     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.3.461     Document Type: Review

References (84)

1. GOSS CH, BROWER RG, HUDSON LD, RUBENFELD GD: Incidence of acute lung injury in the United States. Crit. Care Med. (2003) 31(6):1607- 1611.
2. FRUTOS-VIVAR F, NIN N, ESTEBAN A: Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr. Opin. Crit. Care (2004) 10(1):1-6.
3. MARTIN GS, BERNARD GR: Airway and lung dysfunction in sepsis. Intensive Care Med. (2001) 27(Suppl. 1):S63-S79.
4. BRUN-BUISSON C, MINELLI C, BERTOLINI G et al.: Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med. (2004) 30(1):51-61.
5. BERSTEN AD, EDIBAM C, HUNT T, MORAN J: Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am. J. Respir. Crit. Care Med. (2002) 165(4):443-448.
6. ESTEBAN A, ANZUETO A, FRUTOS F et al.: Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA (2002) 287(3):345-355.
7. THE ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. (2000) 342(18):1301-1308.
8. BROWER RG, LANKEN PN, MACINTYRE N et al.: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N. Engl. J. Med. (2004) 351(4):327-336.
9. ABEL SJ, FINNEY SJ, BRETT SJ, KEOGH BF, MORGAN CJ, EVANS TW: Reduced mortality in association with the acute respiratory distress syndrome (ARDS). Thorax (1998) 53(4):292-294.
10. FOWLER AA, HAMMAN RF, GOOD JT et al.: Adult respiratory distress syndrome: risk with common predispositions. Ann. Intern. Med. (1983) 98(5 Part 1):593-597.
11. MILBERG JA, DAVIS DR, STEINBERG KP, HUDSON LD: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983 - 1993. JAMA (1995) 273(4):306-309.
12. MONTGOMERY AB, STAGER MA, CARRICO CJ, HUDSON LD: Causes of mortality in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. (1985) 132(3):485-489.
13. SLOANE PJ, GEE MH, GOTTLIEB JE et al.: A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am. Rev. Respir. Dis. (1992) 146(2):419-426.
14. WARE LB, MATTHAY MA: The acute respiratory distress syndrome. N. Engl. J. Med. (2000) 342(18):1334-1349.
15. KALLET RH, JASMER RM, PITTET JF et al.: Clinical implementation of the ARDS network protocol is associated with reduced hospital mortality compared with historical controls. Crit. Care Med. (2005) 33(5):925-929.
16. MOORE FA, MOORE EE, READ RA: Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome. N. Horiz. (1993) 1(4):538-549.
17. PAPATHANASSOGLOU ED, MOYNIHAN JA, ACKERMAN MH: Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit. Care Med. (2000) 28(2):537-549.
18. TREMBLAY LN, SLUTSKY AS: Ventilator-induced injury: from barotrauma to biotrauma. Proc. Assoc. Am. Physicians (1998) 110(6):482-488.
19. SLUTSKY AS, TREMBLAY LN: Multiple system organ failure. Is mechanical ventilation a contributing factor? Am. J. Respir. Crit. Care Med. (1998) 157(6 Part 1):1721-1725.
20. AMATO MB, BARBAS CS, MEDEIROS DM et al.: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N. Engl. J. Med. (1998) 338(6):347-354.
21. BROCHARD L, ROUDOT-THORAVAL F, ROUPIE E et al.: Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The multicenter trail group on tidal volume reduction in ARDS. Am. J. Respir. Crit. Care Med. (1998) 158(6):1831-1838.
22. STEWART TE, MEADE MO, COOK DJ et al.: Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and volume-limited ventilation strategy group. N. Engl. J. Med. (1998) 338(6):355-361.
23. THE NATIONAL HEART LUNG AND BLOOD INSTITUTE ARDS CLINICAL TRIAL NETWORK: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N. Engl. J. Med. (2004) 351(4):327-336.
24. VILLAR J, KACMAREK RM, PEREZ-MENDEZ L, GUIRRE-JAIME A: A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. Crit. Care Med. (2006) 34(5): 1311-1318.
25. MEADE MO, COOK DJ, ARABI Y et al.: A multinational randomized controlled trial of a lung open ventilation strategy in ALI/ARDS - preliminary results. Am. J. Respir. Crit. Care Med. (2007):A507.
26. MERCAT A, RICHARD J, BROCHARD L: Comparison of two strategies for setting PEEP in ALI/ARDS (ExPress Study). Am. J. Respir. Crit. Care Med. (2007):A507.
27. FAN E, NEEDHAM DM, STEWART TE: Ventilatory management of acute lung injury and acute respiratory distress syndrome. JAMA (2005) 294(22):2889-2896.
28. SAKR Y, VINCENT J, LE GALL J-R et al.: High tidal volume and positive fluid balance in acute lung injury are associated with worse outcome. Chest (2003) 124:S180.
29. WIEDEMANN HP, WHEELER AP, BERNARD GR et al.: Comparison of two fluid-management strategies in acute lung injury. N. Engl. J. Med. (2006) 354(24):2564-2575.
30. LONG R, BREEN PH, MAYERS I, WOOD LD: Treatment of canine aspiration pneumonitis: fluid volume reduction vs. fluid volume expansion. J. Appl. Physiol. (1988) 65(4): 1736-1744.
31. MOLLOY WD, LEE KY, GIRLING L, PREWITT RM: Treatment of canine permeability pulmonary edema: short-term effects of dobutamine, furosemide, and hydralazine. Circulation (1985) 72(6):1365-1371.
32. HUMPHREY H, HALL J, SZNAJDER I, SILVERSTEIN M, WOOD L: Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure 1. Chest (1990) 97(5):1176-1180.
33. MITCHELL JP, SCHULLER D, CALANDRINO FS, SCHUSTER DP: Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am. Rev. Respir. Dis. (1992) 145(5):990-998.
34. GADEK JE, DEMICHELE SJ, KARLSTAD MD et al.: Effect of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral nutrition in ARDS study group. Crit. Care Med. (1999) 27(8): 1409-1420.
35. WEIGELT JA, NORCROSS JF, BORMAN KR, SNYDERWH III: Early steroid therapy for respiratory failure. Arch. Surg. (1985) 120(5):536-540.
36. BERNARD GR, LUCE JM, SPRUNG CL et al.: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. (1987) 317(25):1565-1570.
37. ADHIKARI N, BURNS KE, MEADE MO: Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst. Rev. (2004) (4):CD004477.
38. MEDURI GU, TOLLEY EA, CHROUSOS GP, STENTZ F: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am. J. Respir. Crit. Care Med. (2002) 165(7):983-991.
39. STEINBERG KP, HUDSON LD, GOODMAN RB et al.: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. (2006) 354(16):1671-1684.
40. SLOTMAN GJ, BURCHARD KW, D'AREZZO A, GANN DS: Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J. Trauma (1988) 28(5):648-654.
41. YU M, TOMASA G: A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med. (1993) 21(11):1635-1642.
42. THE ARDS NETWORK: Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. A randomized controlled trial. JAMA (2000) 283:1995-2002.
43. BERNARD GR, WHEELER AP, RUSSELL JA et al.: The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N. Engl. J. Med. (1997) 336(13):912-918.
44. BERNARD GR, WHEELER AP, ARONS MM et al.: A trial of antioxidants N-acerylcysteine and procysteine in ARDS. The antioxidant in ARDS study group. Chest (1997) 112(1):164-172.
45. IMAI Y, PARODO J, KAJIKAWA O et al.: Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA (2003) 289(16):2104-2112.
46. RANIERI VM, SUTER PM, TORTORELLA C et al.: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome. A randomized controlled trial. JAMA (1999) 281(1):54-61.
47. CROUCH E, WRIGHT JR: Surfactant proteins a and d and pulmonary host defense. Annu. Rev. Physiol. (2001) 63:521-554.
48. LEWIS JF, VELDHUIZEN RA: The future of surfactant therapy during ALI/ARDS. Semin. Respir. Crit. Care Med. (2006) 27(4):377-388.
49. LEWIS JF, VELDHUIZEN RA: The role of exogenous surfactant in the treatment of acute lung injury. Ann. Rev. Physiol. (2003) 65:613-642.
50. ANZUETO A, BAUGHMAN RP, GUNTUPALLI KK et al.: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf acute respiratory distress syndrome sepsis study group. N. Engl. J. Med. (1996) 334(22):1417-1421.
51. SPRAGG RG, LEWIS JF, WALMRATH HD et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. (2004) 351(9):884-892.
52. GREGORY TJ, STEINBERG KP, SPRAGG R et al.: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. (1997) 155(4):1309-1315.
53. ABRAHAM E: Neutrophils and acute lung injury. Crit. Care Med. (2003) 31(Suppl. 4):S195-S199.
54. MULLIGAN MS, PAULSON JC, DE FREES S, ZHENG ZL, LOWE JB, WARD PA: Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 364(6433):149-151.
55. DOERSCHUK CM, QUINLAN WM, DOYLE NA et al.: The role of P-selectin and ICAM-1 in acute lung injury as determined using blocking antibodies and mutant mice. J. Immunol. (1996) 157(10):4609-4614.
56. MATTHAY MA, ZIMMERMAN GA: Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. (2005) 33(4):319-327.
57. ABRAHAM E, BAUGHMAN R, FLETCHER E et al.: Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS study group. Crit. Care Med. (1999) 27(8): 1478-1485.
58. VINCENT JL, BRASE R, SANTMAN F et al.: A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001) 27(10):1578-1583.
59. THE ARDS CLINICAL TRIALS NETWORK, NATIONAL HEART BLOOD AND LUNG INSTITUTE, NATIONAL INSTITUTES OF HEALTH: Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2002) 30(1):1-6.
60. ZIMMERMAN JL, DELLINGER RP, STRAUBE RC, LEVIN JL: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2000) 28(9):3149-3154.
61. RIOUX P: TP-10 (AVANT Immunotherapeutics). Curr. Opin. Investig. Drugs (2001) 2(3):364-371.
62. RITTERSHAUS CW, THOMAS LJ, MILLER DP et al.: Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. (1999) 274(16): 11237-11244.
63. MULLIGAN MS, WARNER RL, RITTERSHAUS CW et al.: Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J. Immunol. (1999) 162(8):4952-4959.
64. TAMAKUMA G, SHIBA T, HIRASAWA H: A Phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. J. Clin Ther. Med. (Japan) (1998) 14:289-318.
65. ZEIHER BG, ARTIGAS A, VINCENT JL at al.: Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit. Care Med. (2004) 32(8):1695-1702.
66. HONORE S, ATTALAH HL, AZOULAY E et al.: Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock (2004) 22(2):131-136.
67. MATTHAY MA, FOLKESSON HG, CLERICI C: Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol. Rev. (2002) 82(3):569-600.
68. SAKUMA T, OKANIWA G, NAKADA T, NISHIMURA T, FUJIMURA S, MATTHAY MA: Alveolar fluid clearance in the resected human lung. Am. J. Respir. Crit. CareMed. (1994) 150(2):305-310.
69. + transport is dependent on β2-adrenergic receptor signaling. Circ. Res. (2004) 94(8):1091-1100.
70. PERKINS GD, MCAULEY DF, THICKETT DR, GAO F: The β-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am. J. Respir. Crit. Care Med. (2006) 173(3):281-287.
71. PRESNEILL JJ, HARRIS T, STEWART AG, CADE JF, WILSON JW: A randomized Phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. (2002) 166(2):138-143.
72. PELAEZ A, BECHARA RI, JOSHI PC, BROWN LA, GUIDOT DM: Granulocyte/ macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lung. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 286(1):L106-L111.
73. PAINE R III, WILCOXEN SE, MORRIS SB et al.: Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am. J. Pathol. (2003) 163(6):2397-2406.
74. MATUTE-BELLO G, LILES WC, RADELLA F et al.: Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit. Care Med. (2000) 28(1):1-7.
75. HIRSCHL RB, CROCE M, GORE D et al.: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. (2002) 165(6):781-787.
76. KACMAREK RM, WIEDEMANN HP, LAVIN PT, WEDEL MK, TUTUNCU AS, SLUTSKY AS: Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. (2006) 173(8):882-889.
77. DELLINGER RP, ZIMMERMAN JL, TAYLOR RW et al.: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized Phase II trial. Inhaled nitric oxide in ARDS study group. Crit. Care Med. (1998) 26(1):15-23.
78. LUNDIN S, MANG H, SMITHIES M, STENQVIST O, FROSTELL C: Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European study group of inhaled nitric oxide. Intensive Care Med. (1999) 25(9):911-919.
79. TAYLOR RW, ZIMMERMAN JL, DELLINGER RP et al.: Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 291(13): 1603-1609.
80. VAN HEERDEN PV, BARDEN A, MICHALOPOULOS N, BULSARA MK, ROBERTS BL: Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest (2000) 117(3):819-827.
81. GOWDA MS, KLOCKE RA: Variability of indices of hypoxemia in adult respiratory distress syndrome. Crit. Care Med. (1997) 25(0:41-45.
82. RUBENFELD GD, CALDWELL E, GRANTON J, HUDSON LD, MATTHAY MA: Interobserver variability in applying a radiographic definition for ARDS. Chest (1999) 116(5):1347-1353.
83. VILLAR J, PEREZ-MENDEZ L, KACMAREK RM: Current definitions of acute lung injury and the acute respiratory distress syndrome do not reflect their true severity and outcome. Intensive Care Med. (1999) 25(9):930-935.
84. ESTEBAN A, FERNANDEZ-SEGOVIANO P, FRUTOS-VIVAR F et al.: Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann. Intern. Med. (2004) 141(6):440-445.